Jun 3 |
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
|
Jun 2 |
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
|
May 30 |
Merus announces pricing of upsized public offering of common shares
|
May 30 |
Merus Announces Pricing of Upsized Public Offering of Common Shares
|
May 29 |
These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat
|
May 29 |
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
|
May 28 |
Merus announces proposed public offering of common shares
|
May 28 |
Merus N.V. Announces Proposed Public Offering of Common Shares
|
May 28 |
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
|
May 27 |
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
|